{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:33:41Z","timestamp":1793392421654,"version":"4.5.0"},"reference-count":242,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","annallergy.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma &amp; Immunology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.anai.2024.09.023","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T14:34:51Z","timestamp":1728484491000},"page":"31-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Identifying super-responders"],"prefix":"10.1016","volume":"134","author":[{"given":"Samuel","family":"Mailhot-Larouche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Celis-Preciado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam G.","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-6886","authenticated-orcid":false,"given":"Simon","family":"Couillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2024.09.023_bib0001","doi-asserted-by":"crossref","unstructured":"Thomas D, McDonald VM, Pavord ID, Gibson PG. Asthma remission: what is it and how can it be achieved? Eur Respir J. 2022;60(5):2102583.","DOI":"10.1183\/13993003.02583-2021"},{"key":"10.1016\/j.anai.2024.09.023_bib0002","doi-asserted-by":"crossref","unstructured":"Fuchs O, Bahmer T, Rabe KF, von Mutius E. Asthma transition from childhood into adulthood. Lancet Respir Med. 2017;5(3):224-234.","DOI":"10.1016\/S2213-2600(16)30187-4"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0003","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.anai.2024.09.023_bib0004","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.jaip.2021.06.041","article-title":"Defining a severe asthma super-responder: findings from a Delphi process","volume":"9","author":"Upham","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0005","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2024.09.023_bib0006","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe asthma network Italy definition of clinical remission in severe asthma: a Delphi consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.anai.2024.09.023_bib0007","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.arbres.2024.04.002","article-title":"Spanish consensus on remission in asthma (REMAS)","volume":"60","author":"\u00c1lvarez-Guti\u00e9rrez","year":"2024","journal-title":"Arch Bronconeumol"},{"issue":"6","key":"10.1016\/j.anai.2024.09.023_bib0008","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, & Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.anai.2024.09.023_bib0009","first-page":"e3","article-title":"Erratum: S2k-Leitlinie zur fach\u00e4rztlichen Diagnostik und Therapie von Asthma 2023 [Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023 - published by the German Respiratory Society (DGP) e.\u200aV.]","volume":"77","author":"Lommatzsch","year":"2023","journal-title":"Pneumologie"},{"key":"10.1016\/j.anai.2024.09.023_bib0010","unstructured":"Asthma GIf. Glob Strategy Asthma Manag Prev. 2024. https:\/\/ginasthma.org\/2024-report\/. Accessed October 22, 2024."},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0011","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.chest.2023.03.001","article-title":"Clinical remission in severe asthma: how to move from theory to practice","volume":"164","author":"Menzies-Gow","year":"2023","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.anai.2024.09.023_bib0012","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/j.jaip.2023.06.059","article-title":"Biologic super-response and clinical remission in severe asthma","volume":"11","author":"Denton","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0013","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jaip.2023.01.021","article-title":"Super-responders to biologic treatment in type 2-high severe asthma: passing fad or a meaningful phenotype?","volume":"11","author":"Portacci","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7040","key":"10.1016\/j.anai.2024.09.023_bib0014","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/bmj.312.7040.1195","article-title":"Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort","volume":"312","author":"Strachan","year":"1996","journal-title":"Bmj"},{"issue":"6947","key":"10.1016\/j.anai.2024.09.023_bib0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/bmj.309.6947.90","article-title":"Factors in childhood as predictors of asthma in adult life","volume":"309","author":"Jenkins","year":"1994","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.anai.2024.09.023_bib0016","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thx.2003.016246","article-title":"Childhood factors associated with asthma remission after 30 year follow up","volume":"59","author":"Vonk","year":"2004","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.06.018","article-title":"Gender differences in asthma development and remission during transition through puberty: the TRacking Adolescents\u2019 Individual Lives Survey (TRAILS) study","volume":"126","author":"Vink","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0018","doi-asserted-by":"crossref","first-page":"00620","DOI":"10.1183\/23120541.00620-2020","article-title":"Remission of adult-onset asthma is rare: a 15-year follow-up study","volume":"6","author":"Almqvist","year":"2020","journal-title":"ERJ Open Res"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0019","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jaip.2020.11.013","article-title":"Remission and changes in severity over 30 years in an adult asthma cohort","volume":"9","author":"Tupper","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0020","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaci.2017.03.034","article-title":"Clinical predictors of remission and persistence of adult-onset asthma","volume":"141","author":"Westerhof","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2024.09.023_bib0021","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.rmed.2016.06.017","article-title":"A 12-year prognosis of adult-onset asthma: Sein\u00e4joki Adult Asthma Study","volume":"117","author":"Tuomisto","year":"2016","journal-title":"Respir Med"},{"issue":"11","key":"10.1016\/j.anai.2024.09.023_bib0022","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/j.rmed.2007.06.011","article-title":"Outcome and severity of adult onset asthma\u2014report from the obstructive lung disease in northern Sweden studies (OLIN)","volume":"101","author":"R\u00f6nmark","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.anai.2024.09.023_bib0023","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pharmthera.2019.05.002","article-title":"A review on the pathophysiology of asthma remission","volume":"201","author":"Carpaij","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0024","doi-asserted-by":"crossref","first-page":"AB4","DOI":"10.1016\/j.jaci.2020.12.061","article-title":"Dupilumab treatment leads to clinical asthma remission in patients with uncontrolled moderate-to-severe asthma with type 2 inflammation","volume":"147","author":"Pavord","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl 66","key":"10.1016\/j.anai.2024.09.023_bib0025","first-page":"2287","article-title":"On-treatment clinical remission with tezepelumab among patients with severe, uncontrolled asthma in the phase 3 NAVIGATOR study","volume":"60","author":"Castro","year":"2022","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0026","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","article-title":"Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with Benralizumab","volume":"39","author":"Menzies-Gow","year":"2022","journal-title":"Adv Ther"},{"issue":"suppl 4","key":"10.1016\/j.anai.2024.09.023_bib0027","first-page":"A272","article-title":"M21 On-treatment clinical remission with tezepelumab in patients with severe, uncontrolled asthma in the phase 3 DESTINATION study","volume":"78","author":"Wechsler","year":"2023","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0028","doi-asserted-by":"crossref","first-page":"AB99","DOI":"10.1016\/j.jaci.2023.11.326","article-title":"Clinical remission outcome in patients with severe asthma with an eosinophilic phenotype (SA-EP) receiving mepolizumab: a post-hoc analysis of a phase 3, randomized, double-blind, placebo-controlled trial","volume":"153","author":"Chen","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0029","doi-asserted-by":"crossref","first-page":"AB266","DOI":"10.1016\/j.jaci.2023.11.851","article-title":"Is asthma clinical remission achievable by inhaled therapy? A post-hoc analysis of single inhaler triple therapy with FF\/UMEC\/VI in the CAPTAIN trial","volume":"153","author":"Lugogo","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2024.09.023_bib0030","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A5267","article-title":"Influence of different thresholds for asthma control on clinical remission composite outcome in patients uncontrolled on ICS\/LABA: a post-hoc analysis of single inhaler triple therapy with FF\/UMEC\/VI in the CAPTAIN trial","volume":"C31","author":"Oppenheimer","year":"2024","journal-title":"What's New Clin Asthma"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0031","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.chest.2024.02.048","article-title":"Effect of azithromycin on asthma remission in adults with persistent uncontrolled asthma: a secondary analysis of a randomized, double-anonymized, placebo-controlled trial","volume":"166","author":"Thomas","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.anai.2024.09.023_bib0032","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2147\/JAA.S391807","article-title":"Long-term efficacy and clinical remission after benralizumab treatment in patients with severe eosinophilic asthma: a retrospective study","volume":"15","author":"Numata","year":"2022","journal-title":"J Asthma Allergy"},{"issue":"12","key":"10.1016\/j.anai.2024.09.023_bib0033","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.3390\/jcm12123953","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with co-presence of bronchiectasis: a real-world multicentre observational study","volume":"12","author":"Campisi","year":"2023","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0034","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical response and remission in patients with severe asthma treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0035","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.3390\/ijms24032455","article-title":"Severe asthma remissions induced by biologics targeting IL5\/IL5r: results from a multicenter real-life study","volume":"24","author":"Maglio","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.anai.2024.09.023_bib0036","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.anai.2024.09.023_bib0037","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jaip.2023.05.047","article-title":"Response to biologics and clinical remission in the adult German asthma net severe asthma registry cohort","volume":"11","author":"Milger","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2024.09.023_bib0038","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.chest.2023.01.037","article-title":"Sputum type 2 markers could predict remission in severe asthma treated with anti-IL-5","volume":"163","author":"Moermans","year":"2023","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.anai.2024.09.023_bib0039","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.3390\/jcm12082900","article-title":"A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma","volume":"12","author":"Oishi","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12931-023-02539-7","article-title":"Achieving clinical outcomes with Benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study","volume":"24","author":"Padilla-Galo","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.anai.2024.09.023_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.anai.2024.09.023_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1121237","article-title":"Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps","volume":"14","author":"Pelaia","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.anai.2024.09.023_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107348","article-title":"Severe asthma clinical remission after biologic treatment with anti-IL4\/IL13: a real-life experience","volume":"217","author":"Portacci","year":"2023","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.anai.2024.09.023_bib0044","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/jpm13061020","article-title":"Clinical asthma remission obtained with biologics in real life: patients\u2019 prevalence and characteristics","volume":"13","author":"Sposato","year":"2023","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0045","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2024","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0046","doi-asserted-by":"crossref","first-page":"219","DOI":"10.23822\/EurAnnACI.1764-1489.318","article-title":"Variables predicting clinical remission among adults with severe asthma treated with biologic agents","volume":"56","author":"Ye\u015filkaya","year":"2024","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2024.09.023_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107528","article-title":"Comparison of clinical remission criteria for severe asthma patients receiving biologic therapy","volume":"222","author":"Breslavsky","year":"2024","journal-title":"Respir Med"},{"key":"10.1016\/j.anai.2024.09.023_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1343362","article-title":"Features of severe asthma response to anti-IL5\/IL5r therapies: identikit of clinical remission","volume":"15","author":"Carpagnano","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.anai.2024.09.023_bib0049","first-page":"1","article-title":"Clinical remission maintained and improved over time in patients with severe asthma treated with omalizumab","author":"Cilli","year":"2024","journal-title":"J Asthma"},{"issue":"7","key":"10.1016\/j.anai.2024.09.023_bib0050","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jaip.2024.03.049","article-title":"Long-term effectiveness of anti-IL-4R therapy following suboptimal response to anti-IL-5\/5R therapy in severe eosinophilic asthma","volume":"12","author":"Gates","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0051","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5414\/CP204495","article-title":"Super-responder and clinical remission in patients with asthma on treatment with single biologic therapy or cycling therapy using dupilumab in a real-world setting","volume":"62","author":"Hamada","year":"2024","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.anai.2024.09.023_bib0052","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1080\/02770903.2024.2332351","article-title":"Real-world clinical remission of severe asthma with benralizumab in Spanish adults with severe asthma","volume":"61","author":"Martinez-Moragon","year":"2024","journal-title":"J Asthma"},{"key":"10.1016\/j.anai.2024.09.023_bib0053","doi-asserted-by":"crossref","unstructured":"Pelaia C, Crimi C, Benfante A, Caiaffa MF, Campisi R, Candia C, et al. Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis [e-pub ahead of print]. Respirology. doi:10.1111\/resp.14767, accessed October 22, 2024.","DOI":"10.1111\/resp.14767"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0054","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/jcm13010291","article-title":"Clinical remission in patients affected by severe eosinophilic asthma on dupilumab therapy: a long-term real-life study","volume":"13","author":"Quarato","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.arbres.2023.11.011","article-title":"Comparison of long-term response and remission to omalizumab and anti-IL-5\/IL-5R using different criteria in a real-life cohort of severe asthma patients","volume":"60","author":"Valverde-Monge","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.anai.2024.09.023_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(24)00293-5","article-title":"Clinical remission attainment, definitions and correlates among biologic-treated patients with severe asthma: a systematic review and meta-analysis","author":"Shackleford","year":"2024","journal-title":"Lancet Respir Med (in press)"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0057","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \u201csuper-responder\u201d to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0058","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-term therapy response to anti-IL-5 biologics in severe asthma\u2014a real-life evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0059","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.anai.2024.09.023_bib0060","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2147\/JAA.S324099","article-title":"A real-world evaluation of clinical outcomes of biologicals and bronchial thermoplasty for severe refractory asthma (BIOTERM)","volume":"14","author":"Menzella","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.anai.2024.09.023_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106595","article-title":"Efficacy of mepolizumab in usual clinical practice and characteristics of responders","volume":"187","author":"Rodr\u00edguez-Garc\u00eda","year":"2021","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.anai.2024.09.023_bib0062","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jaip.2022.02.014","article-title":"Benralizumab effectiveness in severe asthma is independent of previous biologic use","volume":"10","author":"Jackson","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.anai.2024.09.023_bib0063","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.jaip.2023.05.025","article-title":"Long-term real-world outcomes of mepolizumab and benralizumab among biologic-naive patients with severe eosinophilic asthma: experience of 3 years\u2019 therapy","volume":"11","author":"Fyles","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2024.09.023_bib0064","article-title":"Real-world super-response to biologics in severe asthma: a French monocentric retrospective cohort study","volume":"84","author":"Val\u00e9ry","year":"2023","journal-title":"Respir Med Res"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0065","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.2500\/aap.2024.45.230072","article-title":"Real-world effectiveness and predictors of super-responders to dupilumab in a Chinese uncontrolled asthma cohort","volume":"45","author":"Chen","year":"2024","journal-title":"Allergy Asthma Proc"},{"issue":"10","key":"10.1016\/j.anai.2024.09.023_bib0066","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1111\/all.16178","article-title":"Real-world biologics response and super-response in the International Severe Asthma Registry cohort","volume":"79","author":"Denton","year":"2024","journal-title":"Allergy"},{"issue":"10118","key":"10.1016\/j.anai.2024.09.023_bib0067","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(17)30879-6","article-title":"After asthma: redefining airways diseases","volume":"391","author":"Pavord","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.anai.2024.09.023_bib0068","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.jaip.2024.05.016","article-title":"Exploring definitions and predictors of response to biologics for severe asthma","volume":"12","author":"Scelo","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.anai.2024.09.023_bib0069","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring definitions and predictors of severe asthma clinical remission post-biologic in adults","volume":"210","author":"Perez-de-Llano","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2213-2600(22)00185-0","article-title":"Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study","volume":"11","author":"Kole","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.anai.2024.09.023_bib0071","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1378\/chest.07-0713","article-title":"Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study","volume":"132","author":"Lee","year":"2007","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0072","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1378\/chest.112.5.1234","article-title":"Airways obstruction in patients with long-term asthma consistent with \u2018irreversible asthma\u2019","volume":"112","author":"Backman","year":"1997","journal-title":"Chest"},{"issue":"4 Pt 1","key":"10.1016\/j.anai.2024.09.023_bib0073","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1164\/ajrccm.162.4.9912140","article-title":"Duration of asthma and physiologic outcomes in elderly nonsmokers","volume":"162","author":"Cassino","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0074","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/thx.39.2.131","article-title":"Asthma and irreversible airflow obstruction","volume":"39","author":"Brown","year":"1984","journal-title":"Thorax"},{"issue":"3 Pt 1","key":"10.1016\/j.anai.2024.09.023_bib0075","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0091-6749(99)70460-4","article-title":"Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP)","volume":"103","author":"Zeiger","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2024.09.023_bib0076","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1111\/all.15473","article-title":"Biologics and airway remodeling in severe asthma","volume":"77","author":"Varricchi","year":"2022","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.anai.2024.09.023_bib0077","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1164\/ajrccm\/140.6.1745","article-title":"Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity","volume":"140","author":"Jeffery","year":"1989","journal-title":"Am Rev Respir Dis"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0078","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jaci.2008.02.017","article-title":"Expression of smooth muscle and extracellular matrix proteins in relation to airway function in asthma","volume":"121","author":"Slats","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0079","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jaci.2021.01.029","article-title":"Quantitative CT metrics are associated with longitudinal lung function decline and future asthma exacerbations: results from SARP-3","volume":"148","author":"Krings","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.anai.2024.09.023_bib0080","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1164\/ajrccm.164.9.2102039","article-title":"Reduced airway distensibility, fixed airflow limitation, and airway wall remodeling in asthma","volume":"164","author":"Ward","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0081","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/cea.13714","article-title":"Asthma and fixed airflow obstruction: long-term trajectories suggest distinct endotypes","volume":"51","author":"Smith","year":"2021","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0082","first-page":"349","article-title":"Type-2 inflammation and lung function decline in chronic airway disease in the general population","volume":"79","author":"\u00c7olak","year":"2024","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0083","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01785-2017","article-title":"Predictors of accelerated decline in lung function in adult-onset asthma","volume":"51","author":"Coumou","year":"2018","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0084","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02536-2017","article-title":"Associations between blood eosinophils and decline in lung function among adults with and without asthma","volume":"51","author":"Hancox","year":"2018","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0085","doi-asserted-by":"crossref","first-page":"00320","DOI":"10.1183\/23120541.00320-2020","article-title":"Blood eosinophil level and lung function trajectories: cross-sectional and longitudinal studies in European cohorts","volume":"6","author":"Mogensen","year":"2020","journal-title":"ERJ Open Res"},{"issue":"9","key":"10.1016\/j.anai.2024.09.023_bib0086","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1164\/rccm.200702-212OC","article-title":"Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers","volume":"176","author":"Saglani","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.08.044","article-title":"Increased airway smooth muscle in preschool wheezers who have asthma at school age","volume":"131","author":"O'Reilly","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0088","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1165\/rcmb.2018-0009OC","article-title":"Clinical and pathologic factors predicting future asthma in wheezing children. A longitudinal study","volume":"59","author":"Bonato","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0089","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1164\/rccm.202205-0913OC","article-title":"Bronchial remodeling-based latent class analysis predicts exacerbations in severe preschool wheezers","volume":"207","author":"Fayon","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"15","key":"10.1016\/j.anai.2024.09.023_bib0090","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJM200010123431501","article-title":"Long-term effects of budesonide or nedocromil in children with asthma","volume":"343","author":"Szefler","year":"2000","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0091","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jaci.2008.02.029","article-title":"The inhaled steroid treatment as regular therapy in early asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma","volume":"121","author":"Busse","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2024.09.023_bib0092","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.jaci.2009.09.036","article-title":"Thirteen-year follow-up of early intervention with an inhaled corticosteroid in patients with asthma","volume":"124","author":"Haahtela","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0093","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01397-2023","article-title":"The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma","volume":"63","author":"Russell","year":"2024","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0094","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01619-2023","article-title":"Airway remodelling in asthma and the epithelium: on the edge of a new era","volume":"63","author":"Varricchi","year":"2024","journal-title":"Eur Respir J"},{"issue":"21","key":"10.1016\/j.anai.2024.09.023_bib0095","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1014350","article-title":"Effect of bronchoconstriction on airway remodeling in asthma","volume":"364","author":"Grainge","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0096","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1600-065X.2011.01030.x","article-title":"The sentinel role of the airway epithelium in asthma pathogenesis","volume":"242","author":"Holgate","year":"2011","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0097","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jaci.2024.02.011","article-title":"Airway hyperresponsiveness in asthma: the role of the epithelium","volume":"153","author":"Bradding","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"6987","key":"10.1016\/j.anai.2024.09.023_bib0098","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nature02543","article-title":"Mechanotransduction through growth-factor shedding into the extracellular space","volume":"429","author":"Tschumperlin","year":"2004","journal-title":"Nature"},{"issue":"6691","key":"10.1016\/j.anai.2024.09.023_bib0099","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.adk2758","article-title":"Bronchoconstriction damages airway epithelia by crowding-induced excess cell extrusion","volume":"384","author":"Bagley","year":"2024","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.anai.2024.09.023_bib0100","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1152\/japplphysiol.01073.2017","article-title":"Repeated airway constrictions in mice do not alter respiratory function","volume":"124","author":"Mailhot-Larouche","year":"2018","journal-title":"J Appl Physiol (1985)"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0101","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jaip.2017.12.019","article-title":"Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma","volume":"6","author":"Ortega","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0102","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200807-1126OC","article-title":"Severe exacerbations and decline in lung function in asthma","volume":"179","author":"O'Byrne","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0103","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1183\/09031936.00165106","article-title":"Severe exacerbations predict excess lung function decline in asthma","volume":"30","author":"Bai","year":"2007","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.anai.2024.09.023_bib0104","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/thorax-2021-217032","article-title":"Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study","volume":"78","author":"Soremekun","year":"2023","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0105","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01680-2017","article-title":"In vitro, in silico and in vivo study challenges the impact of bronchial thermoplasty on acute airway smooth muscle mass loss","volume":"51","author":"Chernyavsky","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2024.09.023_bib0106","first-page":"1612","volume":"12","author":"Chakir","year":"2015"},{"key":"10.1016\/j.anai.2024.09.023_bib0107","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.rmed.2019.03.005","article-title":"Effect of bronchial thermoplasty on structural changes and inflammatory mediators in the airways of subjects with severe asthma","volume":"150","author":"Ichikawa","year":"2019","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0108","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jaci.2016.08.009","article-title":"Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: clinical and histopathologic correlations","volume":"139","author":"Pretolani","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0109","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jaci.2023.09.035","article-title":"Airway wall extracellular matrix changes induced by bronchial thermoplasty in severe asthma","volume":"153","author":"Wijsman","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0110","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00622-2021","article-title":"Long-term modulation of airway remodelling in severe asthma following bronchial thermoplasty","volume":"59","author":"Jendzjowsky","year":"2022","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.anai.2024.09.023_bib0111","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1513\/AnnalsATS.201603-182LE","article-title":"Long-term effects of bronchial thermoplasty on airway smooth muscle and reticular basement membrane thickness in severe asthma","volume":"13","author":"Salem","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"10.1016\/j.anai.2024.09.023_bib0112","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1164\/rccm.201407-1374LE","article-title":"Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma","volume":"190","author":"Pretolani","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0113","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(20)30408-2","article-title":"Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials","volume":"9","author":"Chaudhuri","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0114","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00930-2019","article-title":"Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma","volume":"54","author":"Chachi","year":"2019","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.anai.2024.09.023_bib0115","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/cea.14489","article-title":"Role of IL-5 in asthma and airway remodelling","volume":"54","author":"AbuJabal","year":"2024","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"10.1016\/j.anai.2024.09.023_bib0116","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1172\/JCI17974","article-title":"Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics","volume":"112","author":"Flood-Page","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.anai.2024.09.023_bib0117","article-title":"Impact of mepolizumab on airway remodelling in severe eosinophilic asthma (abstract)","volume":"209","author":"Taille","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"suppl 67","key":"10.1016\/j.anai.2024.09.023_bib0118","first-page":"OA3152","article-title":"Effect of mepolizumab on airways remodeling in patients with late-onset severe eosinophilic asthma and fixed obstruction (preliminary data of the MESILICO study)","volume":"62","author":"Domvri","year":"2023","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0119","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/039463201202500217","article-title":"Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients","volume":"25","author":"Riccio","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0120","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/02770903.2019.1585872","article-title":"Omalizumab may decrease the thickness of the reticular basement membrane and fibronectin deposit in the bronchial mucosa of severe allergic asthmatics","volume":"57","author":"Zastrze\u017cy\u0144ska","year":"2020","journal-title":"J Asthma"},{"issue":"6","key":"10.1016\/j.anai.2024.09.023_bib0121","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1159\/000334701","article-title":"Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma","volume":"83","author":"Hoshino","year":"2012","journal-title":"Respiration"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0122","doi-asserted-by":"crossref","first-page":"AB368","DOI":"10.1016\/j.jaci.2023.11.879","article-title":"Evaluating the effect of dupilumab on type 2 airway inflammation and mucus plugging in patients with uncontrolled moderate-to-severe asthma: the VESTIGE trial","volume":"153","author":"Castro","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0123","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00417-2022","article-title":"Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design","volume":"9","author":"De Prado Gomez","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.anai.2024.09.023_bib0124","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106228","article-title":"Preventing asthma in high risk kids (PARK) with omalizumab: design, rationale, methods, lessons learned and adaptation","volume":"100","author":"Phipatanakul","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"9643","key":"10.1016\/j.anai.2024.09.023_bib0125","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(08)61452-X","article-title":"Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease","volume":"372","author":"Anderson","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0126","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0127","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/resp.14644","article-title":"Treatable traits models of care","volume":"29","author":"McDonald","year":"2024","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0128","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01509-2019","article-title":"Targeting treatable traits in severe asthma: a randomised controlled trial","volume":"55","author":"McDonald","year":"2020","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0129","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00627-2021","article-title":"NOVELTY: a landmark study in phenotyping and endotyping chronic obstructive airway diseases in real clinical practice","volume":"58","author":"Louis","year":"2021","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.anai.2024.09.023_bib0130","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/resp.14325","article-title":"Treatable traits in the NOVELTY study","volume":"27","author":"Agust\u00ed","year":"2022","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0131","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41533-024-00381-y","article-title":"Change is in the air: key questions on the \u2018Treatable Traits\u2019 model for chronic airway diseases in primary care","volume":"34","author":"Agusti","year":"2024","journal-title":"NPJ Prim Care Respir Med"},{"issue":"6","key":"10.1016\/j.anai.2024.09.023_bib0132","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.chest.2023.04.030","article-title":"Predicting on-biologic remission in asthma: insight from the airways","volume":"163","author":"Couillard","year":"2023","journal-title":"Chest"},{"issue":"10098","key":"10.1016\/j.anai.2024.09.023_bib0133","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0140-6736(17)31448-4","article-title":"Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012)","volume":"390","author":"Ebmeier","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.anai.2024.09.023_bib0134","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","article-title":"The basic immunology of asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0135","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.anai.2024.09.023_bib0136","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3390\/cells11071105","article-title":"The role of airway epithelial cell alarmins in asthma","volume":"11","author":"Whetstone","year":"2022","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.anai.2024.09.023_bib0137","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1016\/j.jaip.2021.02.059","article-title":"Cluster analysis of inflammatory biomarker expression in the international severe asthma registry","volume":"9","author":"Denton","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0138","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of severe asthma worldwide: data from the international severe asthma registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0139","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.anai.2022.02.021","article-title":"Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions","volume":"129","author":"Oppenheimer","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0140","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0141","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12931-016-0482-9","article-title":"Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study","volume":"17","author":"Loza","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.anai.2024.09.023_bib0142","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12931-015-0299-y","article-title":"Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study","volume":"16","author":"Silkoff","year":"2015","journal-title":"Respir Res"},{"issue":"10","key":"10.1016\/j.anai.2024.09.023_bib0143","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1164\/rccm.201604-0866OC","article-title":"A severe asthma disease signature from gene expression profiling of peripheral blood from U-BIOPRED cohorts","volume":"195","author":"Bigler","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.anai.2024.09.023_bib0144","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00413-2021","article-title":"Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma","volume":"58","author":"Kraft","year":"2021","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0145","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.anai.2018.01.030","article-title":"Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma","volume":"120","author":"Chipps","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0146","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s12325-019-01191-2","article-title":"Ability of serum IgE concentration to predict exacerbation risk and benralizumab efficacy for patients with severe eosinophilic asthma","volume":"37","author":"Jackson","year":"2020","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0147","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaip.2022.11.044","article-title":"Dupilumab efficacy in patients with uncontrolled or oral corticosteroid-dependent allergic and nonallergic asthma","volume":"11","author":"Brusselle","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2024.09.023_bib0148","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.rmed.2019.06.004","article-title":"Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility","volume":"154","author":"Humbert","year":"2019","journal-title":"Respir Med"},{"issue":"12","key":"10.1016\/j.anai.2024.09.023_bib0149","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/j.1398-9995.2009.02119.x","article-title":"Relationship between pretreatment specific IgE and the response to omalizumab therapy","volume":"64","author":"Wahn","year":"2009","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0150","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/cea.14256","article-title":"Efficacy of tezepelumab in patients with evidence of severe allergic asthma: results from the phase 3 NAVIGATOR study","volume":"53","author":"Corren","year":"2023","journal-title":"Clin Exp Allergy"},{"issue":"10","key":"10.1016\/j.anai.2024.09.023_bib0151","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/cea.14389","article-title":"Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization","volume":"53","author":"Corren","year":"2023","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0152","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thoraxjnl-2021-217325","article-title":"Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide","volume":"77","author":"Couillard","year":"2022","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0153","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-058215","article-title":"Blood eosinophils, fractional exhaled nitric oxide and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling","volume":"12","author":"Couillard","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0154","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","article-title":"Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial","volume":"9","author":"Lee","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0155","first-page":"332","article-title":"Genetic and T2 biomarkers linked to the efficacy of HDM sublingual immunotherapy in asthma","volume":"79","author":"Hoof","year":"2024","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.anai.2024.09.023_bib0156","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0157","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/all.13302","article-title":"Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma","volume":"73","author":"Casale","year":"2018","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0158","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.anai.2024.09.023_bib0159","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1080\/03007995.2017.1347091","article-title":"The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the phase III SIROCCO and CALIMA studies","volume":"33","author":"Goldman","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.anai.2024.09.023_bib0160","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0161","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jaip.2022.11.043","article-title":"Baseline FeNO independently predicts the dupilumab response in patients with moderate-to-severe asthma","volume":"11","author":"Pavord","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0162","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2023.09.044","article-title":"Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma","volume":"154","author":"Bacharier","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"19","key":"10.1016\/j.anai.2024.09.023_bib0163","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0164","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2024.09.023_bib0165","doi-asserted-by":"crossref","unstructured":"Couillard S, Pavord ID, Heaney LG, Petousi N, Hinks TSC. Sub-stratification of type-2 high airway disease for therapeutic decision-making: a \u2018bomb\u2019 (blood eosinophils) meets \u2018magnet\u2019 (FeNO) framework. Respirology. 2022;27(8):573-577.","DOI":"10.1111\/resp.14294"},{"key":"10.1016\/j.anai.2024.09.023_bib0166","doi-asserted-by":"crossref","unstructured":"Couillard S, Jackson DJ, Pavord ID, Wechsler ME. How I do it. Choosing the right biologic for the right patient with severe asthma [e-pub ahead of print]. Chest. doi:10.1016\/j.chest.2024.08.045, accessed September 6, 2024.","DOI":"10.1016\/j.chest.2024.08.045"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0167","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jaip.2024.01.023","article-title":"Phenotyping of severe asthma in the era of broad-acting anti-asthma biologics","volume":"12","author":"Bourdin","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0168","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaci.2024.01.031","article-title":"Activated sputum eosinophils associated with exacerbations in children on mepolizumab","volume":"154","author":"Wilson","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0169","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1164\/rccm.202305-0808OC","article-title":"Association between T2-related comorbidities and effectiveness of biologics in severe asthma","volume":"209","author":"Wechsler","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12890-019-1040-2","article-title":"Age-specific incidence of allergic and non-allergic asthma","volume":"20","author":"Pakkasela","year":"2020","journal-title":"BMC Pulm Med"},{"issue":"12","key":"10.1016\/j.anai.2024.09.023_bib0171","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/thx.2006.073429","article-title":"Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma","volume":"62","author":"Berry","year":"2007","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.anai.2024.09.023_bib0172","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1164\/rccm.201109-1640OC","article-title":"A large subgroup of mild-to-moderate asthma is persistently noneosinophilic","volume":"185","author":"McGrath","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.anai.2024.09.023_bib0173","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1164\/rccm.201909-1813OC","article-title":"Evidence for exacerbation-prone asthma and predictive biomarkers of exacerbation frequency","volume":"202","author":"Peters","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0174","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1465-9921-11-28","article-title":"Elevation of IL-6 in the allergic asthmatic airway is independent of inflammation but associates with loss of central airway function","volume":"11","author":"Neveu","year":"2010","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0175","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1183\/13993003.01597-2016","article-title":"Interleukin-6 as a biomarker for asthma: hype or is there something else?","volume":"48","author":"Poynter","year":"2016","journal-title":"Eur Respir J"},{"issue":"10095","key":"10.1016\/j.anai.2024.09.023_bib0176","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0177","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00194-2020","article-title":"Airway abundance of <em>Haemophilus influenzae<\/em>predicts response to azithromycin in adults with persistent uncontrolled asthma","volume":"56","author":"Taylor","year":"2020","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.anai.2024.09.023_bib0178","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0179","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0180","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1183\/09031936.00146905","article-title":"Clinical relevance of airway remodelling in airway diseases","volume":"30","author":"James","year":"2007","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0181","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1146\/annurev-physiol-021909-135851","article-title":"It's not all smooth muscle: non-smooth-muscle elements in control of resistance to airflow","volume":"72","author":"Boss\u00e9","year":"2010","journal-title":"Annu Rev Physiol"},{"issue":"3 Pt 1","key":"10.1016\/j.anai.2024.09.023_bib0182","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1164\/ajrccm.149.3.8118625","article-title":"A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists","volume":"149","author":"Suissa","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0183","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jaip.2021.08.006","article-title":"Omalizumab in asthma with fixed airway obstruction: post hoc analysis of EXTRA","volume":"10","author":"Hanania","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2024.09.023_bib0184","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.898208","article-title":"Fixed airflow obstruction in asthma: a problem of the whole lung not of just the airways","volume":"13","author":"Rutting","year":"2022","journal-title":"Front Physiol"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0185","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jaci.2021.07.042","article-title":"Parenchymal destruction in asthma: fixed airflow obstruction and lung function trajectory","volume":"149","author":"Shimizu","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2024.09.023_bib0186","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1016\/j.jaip.2021.08.028","article-title":"Asthma and comorbid conditions-pulmonary comorbidity","volume":"9","author":"Gibson","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3 Pt 2","key":"10.1016\/j.anai.2024.09.023_bib0187","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0091-6749(87)90064-9","article-title":"The presence or absence of bronchial mucus in fatal asthma","volume":"80","author":"Reid","year":"1987","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0188","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0002-9343(03)00260-2","article-title":"The role of mucus in fatal asthma","volume":"115","author":"Hays","year":"2003","journal-title":"Am J Med"},{"issue":"suppl 3","key":"10.1016\/j.anai.2024.09.023_bib0189","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1513\/AnnalsATS.201807-485AW","article-title":"Autopsy and imaging studies of mucus in asthma. Lessons learned about disease mechanisms and the role of mucus in airflow obstruction","volume":"15","author":"Dunican","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"9","key":"10.1016\/j.anai.2024.09.023_bib0190","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1164\/rccm.202110-2265OC","article-title":"Mucus plugs persist in asthma, and changes in mucus plugs associate with changes in airflow over time","volume":"205","author":"Tang","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0191","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0192","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1148\/radiol.2021204616","article-title":"Mucus plugs in asthma at CT associated with regional ventilation defects at (3)he MRI","volume":"303","author":"Mummy","year":"2022","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0193","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.chest.2022.03.003","article-title":"Asthma control, airway mucus, and (129)Xe MRI ventilation after a single benralizumab dose","volume":"162","author":"McIntosh","year":"2022","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0194","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.chest.2023.02.009","article-title":"CT mucus score and (129)Xe MRI ventilation defects after 2.5 years\u2019 anti-IL-5Ralpha in eosinophilic asthma","volume":"164","author":"McIntosh","year":"2023","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.anai.2024.09.023_bib0195","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1164\/rccm.202306-1102LE","article-title":"Effects of dupilumab on mucus plugging and ventilation defects in patients with moderate-to-severe asthma: a randomized, double-blind, placebo-controlled trial","volume":"208","author":"Svenningsen","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.anai.2024.09.023_bib0196","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300135","article-title":"Tezepelumab and mucus plugs in patients with moderate-to-severe asthma","volume":"2","author":"Nordenmark","year":"2023","journal-title":"NEJM Evid"},{"issue":"8","key":"10.1016\/j.anai.2024.09.023_bib0197","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/thx.2006.069682","article-title":"Ventilation heterogeneity is a major determinant of airway hyperresponsiveness in asthma, independent of airway inflammation","volume":"62","author":"Downie","year":"2007","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0198","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaip.2023.09.034","article-title":"Comorbidity burden in severe and nonsevere asthma: a nationwide observational study (FINASTHMA)","volume":"12","author":"Kankaanranta","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0199","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.anai.2023.08.021","article-title":"Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry","volume":"132","author":"Scelo","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/resp.13389","article-title":"Treatable traits can be identified in a severe asthma registry and predict future exacerbations","volume":"24","author":"McDonald","year":"2019","journal-title":"Respirology"},{"issue":"8","key":"10.1016\/j.anai.2024.09.023_bib0201","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/resp.12838","article-title":"Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life","volume":"21","author":"Tay","year":"2016","journal-title":"Respirology"},{"issue":"6","key":"10.1016\/j.anai.2024.09.023_bib0202","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.chest.2021.07.008","article-title":"Workup of severe asthma","volume":"160","author":"Couillard","year":"2021","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0203","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaci.2018.02.004","article-title":"Obesity and asthma","volume":"141","author":"Peters","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0204","article-title":"Uncontrolled asthma in school-aged children-a nationwide specialist care study","volume":"3","author":"Stridsman","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0205","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1164\/rccm.202203-0597OC","article-title":"Skeletal muscle adiposity and lung function trajectory in the severe asthma research program","volume":"207","author":"Tattersall","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.anai.2024.09.023_bib0206","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1164\/rccm.202004-0993OC","article-title":"Asthma exacerbations in patients with type 2 diabetes and asthma on glucagon-like peptide-1 receptor agonists","volume":"203","author":"Foer","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0207","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.rmed.2011.12.012","article-title":"Effect of bariatric surgery on airway response and lung function in obese subjects with asthma","volume":"106","author":"Boulet","year":"2012","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0208","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2011.06.009","article-title":"Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation","volume":"128","author":"Dixon","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0209","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2500\/aap.2023.44.230009","article-title":"Effect of bariatric surgery on lung function and asthma control after 8 years of follow-up","volume":"44","author":"Witte","year":"2023","journal-title":"Allergy Asthma Proc"},{"issue":"7","key":"10.1016\/j.anai.2024.09.023_bib0210","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(23)00187-X","article-title":"Cough and cough hypersensitivity as treatable traits of asthma","volume":"11","author":"Lai","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2024.09.023_bib0211","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105894","article-title":"The impact of dysfunctional breathing on the level of asthma control in difficult asthma","volume":"163","author":"Sedeh","year":"2020","journal-title":"Respir Med"},{"issue":"11","key":"10.1016\/j.anai.2024.09.023_bib0212","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1164\/rccm.201810-1838TR","article-title":"Asthma and obstructive sleep apnea overlap: what has the evidence taught us?","volume":"201","author":"Prasad","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0213","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/ACI.0000000000000705","article-title":"Gastroesophageal reflux and asthma: when, how, and why","volume":"21","author":"Paoletti","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0214","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9030706","article-title":"Physical activity: a missing link in asthma care","volume":"9","author":"Panagiotou","year":"2020","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0215","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5603\/ARM.2020.0087","article-title":"Prevalence of inducible laryngeal obstruction among patients diagnosed as bronchial asthma","volume":"88","author":"Abdelwahab","year":"2020","journal-title":"Adv Respir Med"},{"key":"10.1016\/j.anai.2024.09.023_bib0216","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0217","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03054-2021","article-title":"Low-dose oral corticosteroids in asthma associates with increased morbidity and mortality","volume":"60","author":"Skov","year":"2022","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0218","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaip.2023.01.008","article-title":"Toward a predict and prevent approach in obstructive airway diseases","volume":"11","author":"Couillard","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0219","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jaip.2017.07.034","article-title":"Trends in omalizumab utilization for asthma: evidence of suboptimal patient selection","volume":"6","author":"Jeffery","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0220","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1164\/rccm.201806-1182OC","article-title":"Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma","volume":"199","author":"Heaney","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.anai.2024.09.023_bib0221","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S2213-2600(22)00534-3","article-title":"Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial","volume":"11","author":"Hale","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.anai.2024.09.023_bib0222","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.jaip.2023.03.008","article-title":"Cost-effectiveness of fractional exhaled nitric oxide suppression testing as an adherence screening tool among patients with difficult-to-control asthma","volume":"11","author":"Barry","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.anai.2024.09.023_bib0223","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1016\/j.jaip.2023.06.051","article-title":"Long-term cost-effectiveness of digital inhaler adherence technologies in difficult-to-treat asthma","volume":"11","author":"van de Hei","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0224","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jaip.2023.12.049","article-title":"Cost-effectiveness and impact on health care utilization of interventions to improve medication adherence and outcomes in asthma and chronic obstructive pulmonary disease: a systematic literature review","volume":"12","author":"van Boven","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0225","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.anai.2023.07.017","article-title":"Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study results","volume":"131","author":"Ledford","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2024.09.023_bib0226","doi-asserted-by":"crossref","unstructured":"Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, et al. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype [e-pub ahead of print]. N Engl J Med. doi:10.1056\/NEJMoa2406673, accessed September 9, 2024.","DOI":"10.1056\/NEJMoa2406673"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0227","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1183\/13993003.00850-2016","article-title":"The effect of smoking on lung function: a clinical study of adult-onset asthma","volume":"48","author":"Tommola","year":"2016","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.anai.2024.09.023_bib0228","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1164\/rccm.200511-1746OC","article-title":"Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma","volume":"175","author":"Lazarus","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0229","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/thorax.57.3.226","article-title":"Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma","volume":"57","author":"Chalmers","year":"2002","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2008.06.029","article-title":"Reduction in asthma-related emergency department visits after implementation of a smoke-free law","volume":"122","author":"Rayens","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2024.09.023_bib0231","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaci.2012.12.1574","article-title":"Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma","volume":"131","author":"Thomson","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2024.09.023_bib0232","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/j.jaip.2022.04.034","article-title":"Cigarette smoking and asthma","volume":"10","author":"Thomson","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0233","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.jaci.2018.02.001","article-title":"Effectiveness of indoor allergen reduction in asthma management: a systematic review","volume":"141","author":"Leas","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2024.09.023_bib0234","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMp030082","article-title":"Allergen avoidance in the treatment of asthma and rhinitis","volume":"349","author":"Platts-Mills","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.anai.2024.09.023_bib0235","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMe048177","article-title":"Allergen avoidance to reduce asthma-related morbidity","volume":"351","author":"Sheffer","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2024.09.023_bib0236","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1067\/mai.2002.121317","article-title":"Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study)","volume":"109","author":"M\u00f6ller","year":"2002","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2024.09.023_bib0237","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1398-9995.2006.01068.x","article-title":"Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children","volume":"61","author":"Niggemann","year":"2006","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2024.09.023_bib0238","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/all.13213","article-title":"Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis","volume":"73","author":"Zielen","year":"2018","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.anai.2024.09.023_bib0239","article-title":"Injection allergen immunotherapy for asthma","volume":"8","author":"Abramson","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.anai.2024.09.023_bib0240","article-title":"Sublingual immunotherapy for asthma","volume":"9","author":"Fortescue","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"10.1016\/j.anai.2024.09.023_bib0241","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1001\/jama.2016.3964","article-title":"Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial","volume":"315","author":"Virchow","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.anai.2024.09.023_bib0242","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.jaip.2022.01.046","article-title":"Efficacy and safety of house dust mite sublingual immunotherapy tablet in allergic asthma: a systematic review of randomized controlled trials","volume":"10","author":"Wongsa","year":"2022","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Annals of Allergy, Asthma &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112062401559X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112062401559X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T10:28:17Z","timestamp":1735640897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108112062401559X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":242,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S108112062401559X"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2024.09.023","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying super-responders","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2024.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}